Research ArticleCancer

Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models

See allHide authors and affiliations

Science Translational Medicine  24 Mar 2021:
Vol. 13, Issue 586, eabc6401
DOI: 10.1126/scitranslmed.abc6401

Article Information

vol. 13 no. 586

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication May 5, 2020
  • Resubmitted October 21, 2020
  • Accepted for publication February 5, 2021
  • .

Author Information

  1. Dina Schneider*,,
  2. Ying Xiong*,
  3. Darong Wu,
  4. Peirong Hu,
  5. Leah Alabanza,
  6. Brittany Steimle,
  7. Hasan Mahmud,
  8. Kim Anthony-Gonda,
  9. Winfried Krueger,
  10. Zhongyu Zhu,
  11. Dimiter S. Dimitrov,
  12. Rimas J. Orentas§ and
  13. Boro Dropulić,||
  1. Lentigen, a Miltenyi Biotec Company, Gaithersburg, MD 20878, USA.
  1. Corresponding author. Email: boro.dropulic{at}caringcross.org (B.D.); dina.schneider{at}miltenyi.com (D.S.)
  • * These authors contributed equally to this work.

  • Present address: Center for Antibody Therapeutics, University of Pittsburgh, Pittsburgh, PA 15261, USA.

  • § Present address: Department of Pediatrics, University of Washington School of Medicine, and Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute, Seattle, WA 98101, USA.

  • || Present address: Caring Cross, Gaithersburg, MD 20878, USA.

Altmetric

Article usage

Article usage: March 2021 to July 2021

AbstractFullPdf
Mar 20216008923571
Apr 20211453303283
May 202177710999
Jun 20215427978
Jul 20212997064

Stay Connected to Science Translational Medicine